drugset
drugset / Trial / NCT03953092

A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699

NCT03953092 ↗

Phase 1 Completed 64 enrolled Youngene Therapeutics Inc., Ltd.
RandomizedSequentialTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple ascending oral dose administration.

Timeline

Start
2019-05-01
Primary completion
2019-11-13
Completion
2019-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject YG1699 Small molecule 5 mg Oral
Subject YG1699 Small molecule 10 mg Oral
Subject YG1699 Small molecule 20 mg Oral
Subject YG1699 Small molecule 25 mg Oral
Subject YG1699 Small molecule 50 mg Oral
Subject YG1699 Small molecule 100 mg Oral

Indications

diabetes mellitus